TCR2 Therapeutics (TCRR) Misses Q1 EPS by 26c

TCR2 Therapeutics (NASDAQ: TCRR) reported Q1 EPS of ($1.03), $0.26 worse than the analyst estimate of ($0.77).

For earnings history and earnings-related data on TCR2 Therapeutics (TCRR) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Unifi, Inc. (UFI) Misses Q4 EPS by 11c
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance